Axsome Therapeutics (AXSM) Reports 66% Revenue Growth in FY2025, Beats Analyst Estimates

Axsome Therapeutics Inc. (NASDAQ:AXSM) ranks among the mid-cap stocks to buy according to top investors. On January 20, H.C. Wainwright boosted its price target for Axsome Therapeutics Inc. (NASDAQ:AXSM) to $260 from $200 and kept a Buy rating on the biopharma’s shares. The spike comes after Axsome Therapeutics Inc. (NASDAQ:AXSM) announced interim unaudited financial results for the fourth quarter of 2025, with total product revenue projected to be about $196 million.

Axsome Therapeutics Inc. (NASDAQ:AXSM) expects overall product revenue to be around $638.5 million in fiscal year 2025, an improvement of 66% over fiscal year 2024 and higher than H.C. Wainwright’s prediction of $628.3 million. The company’s primary product, AUVELITY, is projected to bring in net sales of about $155.1 million in Q4 and $507.1 million in the full year 2025, far exceeding the firm’s annual sales estimate of $397 million.

The company’s other products also performed well, with SUNOSI projected to clock in $36.7 million in Q4 revenue and $124.8 million for the year.

Axsome Therapeutics Inc. (NASDAQ:AXSM) is a biopharmaceutical company that develops and delivers novel therapies for the management of central nervous system/CNS disorders in the US.

While we acknowledge the potential of AXSM  as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you're looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.

READ NEXT: 10 Best Magic Formula Stocks for 2025 and 10 Best Retirement Stocks to Buy According to Hedge Funds.

Disclosure: None. This article is originally published at Insider Monkey.